Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells

Phytotherapy Research

Volumn 23, Issue 1, 2009, Pages 86-91

  Hansen, Torstein Schrøder ^a,b   Nilsen, Odd Georg ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Medical Technical Research Center Trondheim   (Norway)

Author keywords

Digoxin; Echinacea; Herb drug interactions; P glycoprotein; Pharmacokinetics

Indexed keywords

ALCOHOL; CARRIER PROTEIN; DIGOXIN; ECHINACEA PURPUREA EXTRACT; GLYCOPROTEIN P; VERAPAMIL;

ALLOSTERISM; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; ECHINACEA PURPUREA; HUMAN; HUMAN CELL; NONHUMAN;

BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; DIGOXIN; ECHINACEA; ETHANOL; HERB-DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; PLANT EXTRACTS; VERAPAMIL;

ECHINACEA PURPUREA;

EID: 58149485468     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2563     Document Type: Article

References (27)

1. Balimane PV, Patel K, Marion A, Chong S. 2004. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur J Pharm Biopharm 58: 99-105.
2. Banan A, Choudhary S, Zhang Y, Fields JZ, Keshavarzian A. 1999. Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. J Pharmacol Exp Ther 291: 1075-1085.
3. Boyd RA, Stern RH, Stewart BH et al. 2000. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.J Clin Pharmacol 40: 91-98.
4. Cavet ME, West M, Simmons NL. 1996. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118: 1389-1396.
5. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. 2004a. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res 21: 819-826.
6. Collett A, Tanianis-Hughes J, Warhurst G. 2004b. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 68: 783-790.
7. Dresser GK, McDonald W, Kim RB, Bailey DG. 2004. Evaluation of herbal products as potential inhibitors of MDR1. Clin Pharmacol Ther 75: 79-79.
8. Eisenberg DM, Davis RB, Ettner SL et al. 1998. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575.
9. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. 1999. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99: 552-557.
10. Gorski JC, Huang SM, Pinto A et al. 2004. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75: 89-100.
11. Hellum BH, Hu Z, Nilsen OG. 2007. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 100: 23-30.
12. Jodoin J, Demeule M, Beliveau R. 2002. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542: 149-159.
13. Kennedy J. 2005. Herb and supplement use in the US adult population. Clin Ther 27: 1847-1858.
14. Keogh JP, Kunta JR. 2006. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27: 543-554.
15. Kligler B. 2003. Echinacea. Am Fam Physician 67: 77-80.
16. Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in phar-macokinetics: clinical implications. Clin Pharmacokinet 42: 59-98.
17. Ma TY, Nguyen D, Bui V, Nguyen H, Hoa N. 1999. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol 276: G965-G974.
18. Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A. 2007. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 59: 567-573.
19. Pal D, Mitra AK. 2006. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78: 2131-2145.
20. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. 2001. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 134: 1601-1608.
21. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134.
22. Wang E, Casciano CN, Clement RP, Johnson WW. 2001. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 18: 800-806.
23. Wang EJ, Barecki-Roach M, Johnson WW. 2002. Elevation of P-glycoprotein function by a catechin in green tea. Biochem Biophys Res Commun 297: 412-418.
24. Yao HM, Chiou WL. 2006. The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 322: 79-86.
25. Yoshida N, Koizumi M, Adachi I, Kawakami J. 2006. Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products. Food Chem Toxicol 44: 2033-2039.
26. Zhang S, Morris ME. 2003. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20: 1184-1191.
27. Zhou S, Lim LY, Chowbay B. 2004. Herbal modulation of P-glycoprotein. Drug Metab Rev 36: 57-104.